When: $432 reclaim AND 200 SMA retest at $477 (both required)

Then: Add remaining 15%

HOLD / WAIT for confirmation before entering

• $477 level represents massive trapped institutional capital and structural resistance - not dismissible as lagging indicator
• Street EPS growth estimate of 38.6% is unconfirmed; if procedure growth deceleration proves durable, forward PEG could expand from 0.85 to 1.3-1.5
• J&J received FDA De Novo authorization - structural competitive shift that compresses multiples regardless of cash flow strength
• Forward P/E of 32.7x faces pressure from elevated rates environment and stagflation risk from Strait of Hormuz closure
• RSI recovery to 60 with 2-4M daily volume vs 11.5M on July 17 capitulation signals bear market relief bounce, not institutional accumulation
• MACD crossover on August 11 occurred inside consolidation range, not confirming breakout above $432-$477 resistance
• Beta of 1.46 means ISRG falls ~14.6% in a 10% market drawdown and ~22% in stagflationary Nasdaq decline
• Entry at $401 with stop at $374 risks 17% loss to $332 prior lows; 50 SMA provides insufficient buffer
• October Q3 earnings is the true test of 'temporary' ACA deferral thesis - two months of uncompensated risk
• Conservative adjustments: reduce to 25% initial position, require $432 reclaim before scaling, widen stop to $365 or $355

→ vs aggressive: 200 SMA is structural resistance representing institutional cost basis, not dismissible as lagging - dismissing it is 'momentum-chasing with extra steps'

→ vs aggressive: Forward PEG of 0.85 requires 38.6% EPS growth to be accurate - can't assume estimates are right while stock price is wrong

→ vs aggressive: J&J FDA De Novo authorization creates structural multiple compression regardless of Ottava's market share trajectory

→ vs aggressive: Fed on hold means elevated rates pressure long-duration equities at 32.7x forward P/E - stagflation worst environment for high-multiple growth

→ vs aggressive: Technical recovery signals (RSI 60, MACD crossover, Bollinger reclaim) are textbook bear market rally patterns after 45% drawdown

→ vs aggressive: High beta of 1.46 cuts both ways - can't embrace volatility for upside while ignoring symmetric downside risk

→ vs aggressive: October earnings is the real test; carrying position through Q3 uncertainty on unconfirmed 'temporary' deferral thesis is hope, not edge

BUY

• Start with 35-40% of intended allocation rather than aggressive 50-60%
• 25% scale-in add at $385-388 on 10 EMA retest
• Final 15% add requires both $432 reclaim AND a close above 200 SMA at $477
• Stop at $374 (below 50 SMA and recent consolidation zone, $27 risk)
• Time-based stop: reduce position by half at mid-September if stock hasn't reclaimed $432 and is consolidating sideways
• Macro invalidation: reduce sizing if oil spikes above $90 and stays for two weeks, or if Fed signals unexpectedly hawkish at September meeting
• Q3 earnings fundamental invalidation: exit position if US procedure growth still decelerating regardless of price
• Market's post-Q2 selloff was rational pricing of forward risks, not irrational behavior
• 200 SMA at $477 represents real structural resistance from underwater institutional holders that must be absorbed
• Q2 printed 18.5% revenue growth and 312 basis points operating margin expansion—documented facts, not untested assumptions

→ vs aggressive: Q2 beat triggered the selloff—the market rationally priced in forward risks (US procedure deceleration, J&J competition) alongside the backward-looking beat. Can't claim great fundamentals while dismissing market's rational repricing.

→ vs aggressive: 50-60% initial sizing is too high given unresolved downtrend and binary nature of next two months before Q3 earnings.

→ vs aggressive: Treatment of 200 SMA as 'just a lagging indicator' is dismissive—structural resistance at $477 from underwater institutional holders is real supply that must be absorbed before sustainable upside.

→ vs conservative: Q2 fundamentals (312 bps margin expansion, record FCF, accelerating buybacks) are documented facts, not untested assumptions—dismissing them is reflexive pessimism, not risk management.

→ vs conservative: Waiting for $432 reclaim before any entry means giving up 8% upside for confirmation that may not come—the scaling approach exists precisely to manage risk incrementally without requiring perfect entry.

→ vs conservative: Widening stop to $365 or $355 is functionally equivalent to not entering—if taking 8% risk, need meaningful upside exposure, which the $374 stop achieves.